Abstract
The results of a high-throughput screening assay using the DENV-2 replicon showed that the 2,4-diaminoquinazoline derivative 4a has a high dengue virus inhibitory activity (EC(50) = 0.15 μM). A series of 2,4-diaminoquinazoline derivatives based on 4a as a lead compound were synthesized and subjected to structure-antidengue activity relationship studies. Among the series of 2,4-diaminoquinazoline derivative probed, 4o was observed to display both the highest antiviral potency (EC(50) = 2.8 nM, SI > 1000) and an excellent pharmacokinetic profile.
© 2012 American Chemical Society
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Antiviral Agents / chemical synthesis*
-
Antiviral Agents / pharmacokinetics
-
Antiviral Agents / pharmacology
-
Cell Line
-
Dengue Virus / drug effects*
-
Dengue Virus / genetics
-
ERG1 Potassium Channel
-
Ether-A-Go-Go Potassium Channels / antagonists & inhibitors
-
High-Throughput Screening Assays
-
Humans
-
Quinazolines / chemical synthesis*
-
Quinazolines / pharmacokinetics
-
Quinazolines / pharmacology
-
Rats
-
Replicon / drug effects
-
Structure-Activity Relationship
Substances
-
5-tert-butoxyquinazoline-2,4-diamine
-
Antiviral Agents
-
ERG1 Potassium Channel
-
Ether-A-Go-Go Potassium Channels
-
Quinazolines